Biohaven EPS - Earnings per Share 2016-2022 | BHVN

Biohaven eps - earnings per share from 2016 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Biohaven Annual EPS
2021 $-13.09
2020 $-13.06
2019 $-10.91
2018 $-6.15
2017 $-5.00
2016 $-5.05
2015 $-0.91
Biohaven Quarterly EPS
2022-09-30 $-1.75
2022-06-30 $-6.21
2022-03-31 $-2.97
2021-12-31 $-4.21
2021-09-30 $-1.38
2021-06-30 $-3.23
2021-03-31 $-4.27
2020-12-31 $-3.64
2020-09-30 $-3.27
2020-06-30 $-3.08
2020-03-31 $-3.07
2019-12-31 $-2.79
2019-09-30 $-2.04
2019-06-30 $-4.67
2019-03-31 $-1.41
2018-12-31 $-1.29
2018-09-30 $-1.53
2018-06-30 $-1.01
2018-03-31 $-2.32
2017-12-31 $-0.29
2017-09-30 $-1.19
2017-06-30 $-1.78
2017-03-31 $-1.74
2016-12-31 $-2.09
2016-09-30 $-2.16
2016-06-30 $-0.55
2016-03-31 $-0.25
2015-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.913B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00